Pretreatment by Rad51-inhibitory substances, namely intravenous low-dose gemcitabine, followed by arterial administration of DNA crosslinking agents into pancreatic arteries was beneficial for patients with locally advanced pancreatic cancers, based on the satisfactory survival time and high rate of CR patients. The gene discussed is RAD51; the disease is pancreatic neoplasm.